Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 7 June 2022 (HL500), which advisory body reviewed the National Institute for Health and Care Research rapid study on those who remain vulnerable to poor outcomes from COVID-19 despite vaccination; and what conclusions it drew from the review.

The Therapeutics Clinical Review Panel periodically reviews new evidence on the definition and revision of eligible cohorts from COVID-19 therapeutics from several sources, including clinical evidence, expert groups and external stakeholders.

The Panel met on 31 January to consider more recent evidence on COVID-19 risk. Expert groups were commissioned to consider the emerging evidence on COVID-19 risk. Their analyses included the National Institute for Health and Care Research rapid study on those who remain vulnerable to poor outcomes from COVID-19 despite vaccination alongside other data sets. The panel is considering these analyses and should any changes to the cohorts eligible for COVID-19 treatments be made an update will be provided.